主动脉内移植物分支闭塞经皮支架置入的长期结局
这项回顾性单中心研究纳入2010年1月至2017年10月间因EVAR后分支闭塞导致间歇性跛行或严重肢体缺血、接受经皮覆膜或裸金属支架置入的11例患者(11条肢体),技术成功10例(90%),无重大并发症,中位随访37.6±25.7个月,5年无再干预生存率100%,无跛行生存率与一期通畅率均为83.33%。作者认为该方式可行、安全,长期结局满意,但需仔细选择患者。
要点
- 11条肢体中10条(90.9%)为间歇性跛行,1例为静息痛,技术成功10例(90%)。
- 无重大并发症,5年无跛行生存率与一期通畅率均为83.33%,无靶病变再干预生存率100%。
- 作者认为该方式可行、安全,长期结局满意,但需仔细选择患者。
核心结论
- 对EVAR后分支闭塞所致慢性缺血行经皮支架置入可行且安全,长期结局满意。
- 作者指出,仔细选择患者是获得临床成功的条件。
研究设计与样本
- 回顾性单中心研究,纳入2010年1月至2017年10月因EVAR后分支闭塞导致间歇性跛行或严重肢体缺血、接受经皮覆膜或裸金属支架置入的患者。
- 29例分支闭塞中11条肢体(11例患者;100%男性;平均年龄71.6±6.9岁)接受经皮治疗并纳入分析。
- 急性肢体缺血病例接受手术治疗并被排除。
主要发现
- 多数患者为间歇性跛行(10/11;90.9%),1例为静息痛。
- 技术成功10例(90%),无重大并发症。
- 平均随访37.6±25.7个月。
- 支架以覆膜支架为主,2例(18.18%)仅置入镍钛裸支架。
- Kaplan-Meier分析显示,随访至5年时无跛行生存率与一期通畅率均为83.33%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To investigate the safety and efficacy of percutaneous stenting for the management of chronic ischemia caused by endograft limb occlusion following endovascular aortic aneurysm repair (EVAR). METHODS: This is a retrospective, single-center study investigating all patients who underwent percutaneous endovascular covered or bare metal stent placement for the management of intermittent claudication (IC) or critical limb ischemia following EVAR limb occlusion, between January 2010 and October 2017. Cases suffering from acute limb ischemia were treated surgically and were excluded from the analysis. Primary outcome measures were technical success and symptoms-free interval. Secondary outcome measures included clinically driven target-lesion reintervention (TLR)-free survival, primary patency, and complication rates. RESULTS: Of 29 limb occlusions, 11 limbs (11 patients; 100% male; mean age: 71.6 ± 6.9 years) were treated percutaneously and were included in the study. The majority suffered from IC (10/11; 90.9%) with a single case of rest pain. Technical success was obtained in 10 patients (90%). No major complications occurred. Mean follow-up time was 37.6 ± 25.7 months. Stent grafts were mainly used, while and in 2 cases (18.18%), only nitinol bare stents were deployed. According to Kaplan-Meier analysis, both symptoms-free interval and primary patency were 83.33% in up to 5 years follow-up. TLR-free survival was 100% at 5 years, as 2 cases of claudication relapse were managed conservatively. CONCLUSIONS: Percutaneous stenting for the management chronic ischemia due to EVAR limb occlusion is feasible and safe, with satisfactory long-term outcomes. Careful patient selection warrants clinical success.
引用
- Spiliopoulos S, Moulakakis K, Palialexis K, et al. Long-Term Outcomes of Percutaneous Stenting of Aortic Endograft Limb Occlusion. Ann Vasc Surg. 2018. PMID: 30092436. doi:10.1016/j.avsg.2018.05.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。